Using the direct-injection model of early uveal melanoma hepatic metastasis to identify TPS as a potentially useful serum biomarker

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 10, 2007, Pages 4399-4402

  Barak, Vivian ^a   Frenkel, Shahar ^a   Valyi Nagy, Klara ^b   Leach, Lu ^b   Apushkin, Marsha A ^b   Lin, Amy Y ^b   Kalickman, Inna ^a   Baumann, Nikola A ^b   Pe'er, Jacob ^a   Maniotis, Andrew J ^b   Folberg, Robert ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 18; TUMOR MARKER; PEPTIDE; TISSUE POLYPEPTIDE SPECIFIC ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE MARKER; ECHOGRAPHY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; LIVER METASTASIS; LIVER NODULE; MAJOR CLINICAL STUDY; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; UVEA MELANOMA; ANIMAL; BLOOD; CELL CULTURE; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; LIVER TUMOR; MELANOMA; METASTASIS; MOUSE MUTANT; PATHOLOGY; UVEA TUMOR;

ANIMALS; ANTIGENS, NEOPLASM; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; HUMANS; KERATIN-18; LIVER NEOPLASMS; MELANOMA; MICE; MICE, SCID; PEPTIDES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; UVEAL NEOPLASMS;

EID: 35748943863     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.07-0552     Document Type: Article

References (31)

1. McLean IW. The biology of haematogenous metastasis in human uveal malignant melanoma. Virchows Arch A Pathol Anat. 1993;422:433-437.
2. Kaiserman I, Amer R, Pe'er J. Liver function tests in metastatic uveal melanoma. Am J Ophthalmol. 2004;137:236-243.
3. Donoso LA, Shields JA, Augsburger JA, Orrh DH, Johnson P. Metastatic uveal melanoma: diffuse hepatic metastasis in a patient with concurrent normal serum enzyme levels and liver scan. Arch Ophthalmol. 1985;103:758-758.
4. Hicks C, Foss AJ, Hungerford JL. Predictive power of screening tests for metastasis in uveal melanoma. Eye. 1998;12(pt 6):945-948.
5. Rivoire M, Kodjikian L, Baldo S, Kaemmerlen P, Negrier S, Grange JD. Treatment of liver metastases from uveal melanoma. Ann Surg Oncol. 2005;12:422-428.
6. Kadkol SS, Lin AY, Barak V, et al. Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. Invest Ophthalmol Vis Sci. 2006;47:802-806.
7. Reiniger IW, Wolf A, Welge-Lussen U, Mueller AJ, Kampik A, Schaller UC. Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study. Am J Ophthalmol. 2007;143:705-707.
8. Mlssotten GS, Tang NE, Korse CM, et al. Prognostic value of S-100-beta serum concentration in patients with uveal melanoma. Arch Ophthalmol. 2003;121:1117-1119.
9. Reiniger IW, Schaller UC, Haritoglou C, et al. "Melanoma inhibitory activity" (MIA): a promising serological tumour marker in metastatic uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 2005;243:1161-1166.
10. Barak V, Frenkel S, Kalickman I, Maniotis AJ, Folberg R, Pe'er J. Serum markers to detect metastatic uveal melanoma. Anticancer Res. 2007;27:1897-1900.
11. Zuidervaart W, van der Velden PA, Hurks MH, et al. Gene expression profiling identifies tumour markers potentially playing a role in uveal melanoma development. Br J Cancer. 2003;89:1914-1919.
12. Folberg R, Arbieva Z, Moses J, et al. Tumor cell plasticity in uveal melanoma: microenvironment directed dampening of the invasive and metastatic genotype and phenotype accompanies the generation of vasculogenic mimicry patterns. Am J Pathol. 2006;169:1376-1389.
13. Missotten GS, Beijnen JH, Keunen JEE, Bonfrer JMG. Proteomics in uveal melanoma. Mel Res. 2003;13:627-629.
14. Pardo M, Garcia A, Thomas B, et al. Proteome analysis of a human uveal melanoma primary cell culture by 2-DE and MS. Proteomics. 2005;5:4980-4993.
15. Zuidervaart W, Hensbergen P, Wong MC, et al. Proteomic analysis of uveal melanoma reveals novel potential markers involved in tumor progression. Invest Ophthalmol Vis Sci. 2006;47:786-793.
16. Folberg R, Leach L, Valyi-Nagy K, et al. Modeling the behavior of uveal melanoma cells in the liver. Invest Ophthalmol Vis Sci. 2007;48:2967-2974.
17. Hendrix MJC, Seftor EA, Seftor RB, et al. Biologic determinants of uveal melanoma metastatic phenotype - role of intermediate filaments as predictive markers. Lab Invest. 1998;78:153-163.
18. Barak V, Nisman B, Hubert A, Lyass O, Kaduri L, Peretz T. Prognostic efficacy of TPS in breast cancer. J Tumor Marker Oncol. 2000;15:4-10.
19. Einarsson R, Barak V. TPS: a cytokeratin serum tumor marker for effective therapy control of cancer patients with focus on breast cancer. J Clin Ligand Assay. 2000;22:348-352.
20. Nisman B, Lafair J, Heching N, et al. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information? Cancer. 1998;82:1850-1859.
21. Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry Am J Pathol. 1999;155:739-752.
22. Maniotis AJ, Valyi-Nagy K, Karavitis J, et al. Chromatin sensitivity to Alu I endonuclease is regulated by extracellular matrix and the cytoskeleton. Am J Pathol. 2005;166:1187-1203.
23. Maniotis AJ, Chen X, Garcia C, et al. Control of melanoma morphogenesis, endothelial survival, and perfusion by extracellular matrix. Lab Invest. 2002;82:1031-1043.
24. Kollmar O, Schilling MK, Menger MD. Experimental liver metastasis; standards for local cell implantation to study isolated tumor growth in mice. Clin Exp Metastasis. 2004;21:453-460.
25. Braun RD, Abbas A, Bukhari SO, Wilson W. Hemodynamic parameters in blood vessels in choroidal melanoma xenografts and rat choroid. Invest Ophthalmol Vis Sci. 2002;43:3045-3052.
26. Oshima RG, Millan JL, Cecena G. Comparison of mouse and human keratin 18: a component of intermediate filaments expressed prior to implantation. Differentiation. 1986;33:61-68.
27. Hicks C, Foss AJE, Hungerford JL. Predictive power of screening tests for metastasis in uveal melanoma. Eye. 1998;12:945-948.
28. Char DH. Metastatic choroidal melanoma. Am J Ophthalmol. 1978;86:76-80.
29. Eskelin S, Kivela T. Mode of presentation and time to treatment of uveal melanoma in Finland. Br J Ophthalmol. 2002;86:333-338.
30. Diener-West M, Reynolds SM, Agugliaro DJ, et al. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol. 2004;22:2438-2444.
31. Gonzalez-Quintela A, Garcia J, Campos J, et al. Serum cytokeratins in alcoholic liver disease: contrasting levels of cytokeratin-18 and cytokeratin-19. Alcohol. 2006;38:45-49.